Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raoul Tibes

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
The New England Journal of Medicine|September 4, 2009
Inhibition of the hedgehog pathway in advanced basal-cell carcinomaDaniel D Von Hoff, Patricia M LoRusso, Charles M Rudin, et al.
Cancer Cell|February 26, 2019
Targeting an RNA-Binding Protein Network in Acute Myeloid LeukemiaEric Wang, Sydney X Lu, Alessandro Pastore, et al.
The Lancet. Haematology|May 8, 2019
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trialGuillermo Garcia-Manero, Gail Roboz, Katherine Walsh, et al.
Communications Biology|June 26, 2021
Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemiaAndoni Garitano-Trojaola, Ana Sancho, Ralph Götz, et al.
Haematologica|May 30, 2015
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemiaJoshua F Zeidner, Matthew C Foster, Amanda L Blackford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumorsGeoffrey I Shapiro, Raoul Tibes, Michael S Gordon, et al.
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.
Blood|May 5, 2018
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, et al.
Blood|August 13, 2017
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterationsBenjamin H Durham, Bartlomiej Getta, Sascha Dietrich, et al.
The Lancet. Oncology|August 29, 2017
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trialHagop M Kantarjian, Gail J Roboz, Patricia L Kropf, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|September 4, 2009
Inhibition of the hedgehog pathway in advanced basal-cell carcinomaDaniel D Von Hoff, Patricia M LoRusso, Charles M Rudin, et al.
Cancer Cell|February 26, 2019
Targeting an RNA-Binding Protein Network in Acute Myeloid LeukemiaEric Wang, Sydney X Lu, Alessandro Pastore, et al.
The Lancet. Haematology|May 8, 2019
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trialGuillermo Garcia-Manero, Gail Roboz, Katherine Walsh, et al.
Communications Biology|June 26, 2021
Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemiaAndoni Garitano-Trojaola, Ana Sancho, Ralph Götz, et al.
Haematologica|May 30, 2015
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemiaJoshua F Zeidner, Matthew C Foster, Amanda L Blackford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumorsGeoffrey I Shapiro, Raoul Tibes, Michael S Gordon, et al.
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.
Blood|May 5, 2018
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, et al.
Blood|August 13, 2017
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterationsBenjamin H Durham, Bartlomiej Getta, Sascha Dietrich, et al.
The Lancet. Oncology|August 29, 2017
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trialHagop M Kantarjian, Gail J Roboz, Patricia L Kropf, et al.
Pageof 8